Summary
44 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 16% this fiscal year.
What to watch
- Revenue fell by 36% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 30.5 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 18% a year over 5 years. Over the last 3 years it fell by 36% a year. For the next fiscal year analysts expect revenue to grow by 16%. Earnings per share fell by 42% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 3.0 USD
- Research and development 19 USD
- Sales and administration 7.6 USD
- Taxes and other 5.6 USD
- Net profit 8.2 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 8.2 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 4
- Sell 2
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detail